Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data

Larotrectinib, a highly specific tropomyosin receptor kinase (TRK) inhibitor, previously demonstrated high response rates in single-arm trials of patients with TRK fusion-positive cancer, but there are limited data on comparative effectiveness against standard-of-care (SoC) regimens used in routine...

Descripción completa

Detalles Bibliográficos
Autores principales: Bokemeyer, Carsten, Paracha, Noman, Lassen, Ulrik, Italiano, Antoine, Sullivan, Sean D., Marian, Marisca, Brega, Nicoletta, Garcia-Foncillas, Jesus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928633/
https://www.ncbi.nlm.nih.gov/pubmed/36689698
http://dx.doi.org/10.1200/PO.22.00436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928633/
https://www.ncbi.nlm.nih.gov/pubmed/36689698
http://dx.doi.org/10.1200/PO.22.00436

Ejemplares similares